While targeting MYC in TNBC is an area of active research [20–22], targeting transcription provides a means to simultaneously target MYC as well as other oncogenic drivers of TNBC, thereby circumventing the problem of patient and tumour heterogeneity [23]. Here, MYC is linked to neoplasm.